Fused heterocyclic derivative and use thereof
AssigneeTakeda Pharmaceutical Company Limited
InventorsNozomu Sakai, Shinichi Imamura, Naoki Miyamoto, Takaharu Hirayama
Life of this patent
Estimating the term…
Abstract
The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
Claims2
N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide or a salt or a prodrug thereof.
Dependencies are inferred from the claim text.